Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial.
Mikkelsen MK, Lund CM, Vinther A, Tolver A, Johansen JS, Chen I, Ragle AM, Zerahn B, Engell-Noerregaard L, Larsen FO, Theile S, Nielsen DL, Jarden M. Mikkelsen MK, et al. Among authors: larsen fo. Oncologist. 2022 Feb 3;27(1):67-78. doi: 10.1002/onco.13970. Oncologist. 2022. PMID: 34498352 Free PMC article. Clinical Trial.
Engaging the older cancer patient; Patient Activation through Counseling, Exercise and Mobilization - Pancreatic, Biliary tract and Lung cancer (PACE-Mobil-PBL) - study protocol of a randomized controlled trial.
Mikkelsen MK, Lund CM, Vinther A, Tolver A, Ragle AM, Johansen JS, Chen I, Engell-Noerregaard L, Larsen FO, Zerahn B, Nielsen DL, Jarden M. Mikkelsen MK, et al. Among authors: larsen fo. BMC Cancer. 2018 Sep 27;18(1):934. doi: 10.1186/s12885-018-4835-2. BMC Cancer. 2018. PMID: 30261853 Free PMC article.
Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
Jensen BV, Schou JV, Yilmaz M, Johannesen HH, Skougaard K, Linnemann D, Hogdall EV, Larsen FO, Johansen JS, Pfeiffer P, Nielsen DL. Jensen BV, et al. Among authors: larsen fo. Int J Cancer. 2021 May 15;148(10):2542-2556. doi: 10.1002/ijc.33448. Epub 2020 Dec 30. Int J Cancer. 2021. PMID: 33336394 Free article.
Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer.
Lindgaard SC, Brinch CM, Jensen BK, Nørgaard HH, Hermann KL, Theile S, Larsen FO, Jensen BV, Michelsen H, Nelausen KM, Holm VH, Ekblad L, Soerensen PG, Nielsen DL. Lindgaard SC, et al. Among authors: larsen fo. Breast. 2019 Feb;43:113-119. doi: 10.1016/j.breast.2018.12.002. Epub 2018 Dec 5. Breast. 2019. PMID: 30544058 Clinical Trial.
Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up.
Abrahamsson H, Jensen BV, Berven LL, Nielsen DL, Šaltytė Benth J, Johansen JS, Larsen FO, Johansen JS, Ree AH. Abrahamsson H, et al. Among authors: larsen fo. Int J Cancer. 2020 Apr 1;146(7):2019-2026. doi: 10.1002/ijc.32847. Epub 2020 Jan 7. Int J Cancer. 2020. PMID: 31872440 Free article.
Risk factors for brain metastases in patients with metastatic colorectal cancer.
Christensen TD, Palshof JA, Larsen FO, Høgdall E, Poulsen TS, Pfeiffer P, Jensen BV, Yilmaz MK, Christensen IJ, Nielsen D. Christensen TD, et al. Among authors: larsen fo. Acta Oncol. 2017 May;56(5):639-645. doi: 10.1080/0284186X.2017.1290272. Epub 2017 Feb 22. Acta Oncol. 2017. PMID: 28447565
45 results